Theravance Biopharma Stock Today
| TBPH Stock | USD 9.36 0.11 1.16% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Theravance Biopharma is trading at 9.36 as of the 21st of March 2025. This is a 1.16 percent decrease since the beginning of the trading day. The stock's open price was 9.47. Theravance Biopharma has about a 35 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of May 2014 | Category Healthcare | Classification Health Care |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. The company has 49.47 M outstanding shares of which 3.94 M shares are at this time shorted by private and institutional investors with about 14.65 trading days to cover. More on Theravance Biopharma
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Theravance Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite Total, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTheravance Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theravance Biopharma's financial leverage. It provides some insight into what part of Theravance Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Theravance Biopharma (TBPH) is traded on NASDAQ Exchange in USA. It is located in 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 and employs 97 people. Theravance Biopharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 468.49 M. Theravance Biopharma conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 49.47 M outstanding shares of which 3.94 M shares are at this time shorted by private and institutional investors with about 14.65 trading days to cover.
Theravance Biopharma currently holds about 132.85 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74.
Check Theravance Biopharma Probability Of Bankruptcy
Ownership AllocationTheravance Biopharma shows a total of 49.47 Million outstanding shares. The majority of Theravance Biopharma outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Theravance Biopharma to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Theravance Biopharma. Please pay attention to any change in the institutional holdings of Theravance Biopharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Theravance Ownership Details
Theravance Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-12-31 | 833.9 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 553.7 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 495.7 K | |
| Bank Of America Corp | 2024-12-31 | 481.5 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 438.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 392.3 K | |
| Northern Trust Corp | 2024-12-31 | 390 K | |
| Citadel Advisors Llc | 2024-12-31 | 314.6 K | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 305.6 K | |
| Madison Avenue Partners, Lp | 2024-12-31 | 9.5 M | |
| Weiss Asset Management Lp | 2024-12-31 | 7.5 M |
Theravance Biopharma Historical Income Statement
Theravance Stock Against Markets
Theravance Biopharma Corporate Management
| Rhonda Farnum | Chief Affairs | Profile | |
| Andrew MBA | VP CFO | Profile | |
| Stacy Pryce | Senior Officer | Profile | |
| Stuart Knight | Senior Officer | Profile | |
| Gail Cohen | Vice Relations | Profile | |
| Rick MBA | Chairman CEO | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share | Quarterly Revenue Growth 0.068 | Return On Assets | Return On Equity |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.